https://doi.org/10.48047/AFJBS.6.14.2024.3153-3163

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Challenges in Detecting Genotoxic Impurities in API Manufacturing

Manoj Kumar Rathore*[1], Dr. Rajkumari Thagele[2]

[1]*Research Scholar, Career Point School of Pharmacy, Career Point University, Kota, Rajasthan*

[2]*Professor, Career Point School of Pharmacy, Career Point University, Kota, Rajasthan*

Corresponding Author: manoj_rathore2001@yahoo.com

Volume 6, Issue 14, Aug 2024

Received: 09 June 2024

Accepted: 19 July 2024

Published: 11 Aug 2024

doi: 10.48047/AFJBS.6.14.2024.3153-3163

Abstract

Recent advances in both the US and Europe were discussed at the symposium on genotoxic impurities in pharmaceutical synthesis, which emphasised the need for sponsors of new drug applications to put measures in place to reduce the risks associated with possible genotoxic impurities. These contaminants need further scrutiny beyond that of the more general International Conference on Harmonisation (ICH) Q3A/Q3B recommendations as conventional genotoxicity testing for medicinal compounds can fail to prove that they are safe. A more exact risk characterisation may be appropriate in some situations, but the symposium argued that the threshold of toxicological concern (TTC) should serve as the baseline for risk management. Several real-world examples were given to illustrate the process of pharmaceutical synthesis and the introduction and management of contaminants. New developments in regulation were also addressed, including the idea of a "staged threshold of toxicological concern," which is applicable to situations involving short-term administration, such as clinical trials.

Keywords: genotoxic impurities, pharmaceutical synthesis, risk management, ICH guidelines, toxicological concern, regulatory developments, safety qualification, drug impurities, short-term administration, threshold analysis.

1. Introduction

Genotoxic impurities (GIs) pose serious problems for pharmaceutical businesses and regulatory bodies when they are involved in the production of Active Pharmaceutical Ingredients (APIs). Because GIs may induce cancer and genetic abnormalities, strict control measures are necessary to protect patients. The synthetic procedures used to make APIs are complicated, and the contaminants are often present in very low amounts, making detection a difficult operation. Recent changes in regulatory guidelines and business practices have

highlighted the need of accurate identification and treatment of GIs, which is becoming more important as the pharmaceutical sector progresses.

The International Conference on Harmonisation (ICH) has issued guidelines that highlight the need of identifying and controlling contaminants in pharmaceutical products and substances. The International Conference on Harmonisation (ICH) established recommendations Q3A(R2), Q3B(R2), and Q3C(R4) for the testing of contaminants in medicines. These standards must be followed in order for medications to be sold safely. Despite these efforts, US and European regulatory authorities have come out with additional suggestions to deal with genotoxic pollutants as the standards don't cover that. An example of this is the need for a more focused approach to managing genotoxic contaminants; a guideline addressing these limitations has been produced by the European Medicines Agency (EMA) (Committee for Medicinal Products for Human Use, European Medicines Agency, 2006).

Furthermore, according to the United States Food and Drug Administration (2008), the pharmaceutical sector and its products include genotoxic and carcinogenic contaminants. To address this, the FDA has issued recommendations for their management. These regulatory frameworks are crucial because they provide the groundwork for pharmaceutical corporations to evaluate and manage gastrointestinal concerns. In order to achieve successful risk management, structure-based evaluations and toxicological concern thresholds (TTC) are often used (Kroes et al., 2004; Munro et al., 1999). To improve the identification and control of genotoxic contaminants, and hence to protect the general population's health, regulatory standards and industrial innovations must continue to evolve.

2. Evolving Regulatory Expectations and Guidelines

Concerning the management of genotoxic contaminants in the pharmaceutical development process, regulatory agencies in both Europe and the United States have increased their level of scrutiny. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) of the United States have produced guidance guidelines that require sponsors of new drug applications to develop mechanisms that manage the risks that are presented by possible gastrointestinal (GI) substances. The special dangers that are presented by gastrointestinal (GI) compounds are not adequately covered by the guidelines Q3A and Q3B of the International Conference on Harmonisation (ICH), which are concerned with the safety of drug substances and goods, respectively. As a consequence of this, new regulatory measures,

such as the threshold of toxicological concern (TTC), have been implemented in order to manage these risks in a more efficient manner.

Table 1: Regulatory Guidelines Overview

Regulatory Body	Guideline	Key Focus	Implementation Date
EMA	Q3A(R2)	Impurities in New Drug Substances	2006
FDA	Q3B(R2)	Impurities in New Drug Products	2008
ICH	Q3C(R4)	Residual Solvents	2009

A "staged TTC," a concept recently added to regulations, permits greater permissible levels of GIs during short-term exposure, such in clinical studies, thanks to recent advancements. The need to strike a compromise between expediting drug development and guaranteeing safety is reflected in this adaptive strategy. On the other hand, these ever-changing laws bring attention to the fact that API manufacturers need better detection systems and stronger risk management procedures.

3. Analytical Challenges in Detecting Genotoxic Impurities

It is analytically challenging to detect genotoxic contaminants in APIs. The manufacture of APIs often employs synthetic techniques that include many starting materials, intermediates, and reagents. These substances may all have a role in the development of GIs. Because these contaminants are usually present at such low concentrations, conventional analytical procedures have a hard time picking them up. In addition, unanticipated and even difficult-to-identify contaminants might be formed as a result of the synthetic pathways' complexity.



Graph 1: Detection Sensitivity of Analytical Methods

Note: This graph illustrates the sensitivity of various analytical methods used to detect GIs in API manufacturing. Higher bars indicate greater sensitivity, necessary for detecting lower concentrations of impurities.

Additional difficulties arise in the early phases of drug development due to the fact that analytical technologies required to detect and quantify contaminants are still in the works and synthetic procedures have not yet reached complete optimisation. It is common to use higher identification and qualification criteria in the early stages of development due to the lack of expertise and analytical skills. The development of increasingly sensitive and specialised analytical procedures is necessary because more rigorous controls are needed as the medicine moves through clinical trials and towards registration.

4. Strategic Approaches for Managing Genotoxic Impurities

Combining regulatory recommendations with industry standards requires a multipronged strategy for genotoxic impurity risk management. To provide a cautious safety limit for GIs when there is a lack of particular toxicity data, the TTC is an important tool in this procedure. Based on a probability distribution of recognised carcinogens, the TTC concept—which was borrowed from food safety—provides a toxicological threshold below which the risk of cancer is insignificant.

A permitted daily exposure (PDE) may be determined for GIs with known threshold mechanisms, enabling more accurate risk management. As a default risk management tool,

however, the TTC is useful for contaminants whose threshold mechanism is unclear. To ensure patient safety, it is vital to take this cautious approach, especially in the early phases of drug development when there is insufficient evidence on toxicity.

Table 2: Risk Management Strategies for Genotoxic Impurities

Impurity Category	Mechanism	Risk Management Approach	TTC (µg/day)
Category 1	Known Genotoxicity	PDE	1.5
Category 2	Unknown Genotoxicity	TTC	1.5
Category 3	Suspected Genotoxicity	Ames Test	Varies

When it comes to mitigating the dangers of genotoxic contaminants, industry standards are equally important. In order to detect any possible GIs, companies usually do structure-based evaluations of all raw materials and intermediates used in API synthesis. Following these evaluations—which are often performed using in silico tools like DEREK—detailed fate assessments are carried out to ascertain if the impurity will be eliminated throughout the synthetic process or whether it necessitates analytical monitoring and control procedures.

5. Practical Applications: Industry Case Studies

In response to real-world case studies, the pharmaceutical industry has implemented several methods to mitigate the dangers of genotoxic contaminants. The genotoxic contaminant ethyl methanesulfonate (EMS) was found in Viracept (nelfinavir mesylate) tablets, for instance. Thousands of HIV patients were exposed to EMS levels much over what is considered tolerable due to the 2007 event that happened in Europe. The significance of conducting comprehensive risk assessments at every stage of medication development and the need for tight control mechanisms were both brought to light by this instance.



Graph 2: Case Study - EMS Contamination Impact on Drug Safety

Note: This graph demonstrates the impact of EMS contamination on the safety profile of Viracept, showing the correlation between EMS levels and the associated cancer risk.

A battery of preclinical studies was carried out by the holder of the marketing authorisation in order to get a better understanding of the possible hazards that may be posed by EMS and to put safeguards in place to prevent a tragedy similar to the one that occurred with Viracept. As seen in these and other cases, toxicologists, synthetic chemists, and analytical scientists need to collaborate in order to take preventative measures in order to control genotoxic pollutants.

6. Advancements in Analytical Techniques

As a result of the introduction of new technologies and approaches, the identification of genotoxic contaminants in the manufacture of API is undergoing a process of evolution. High-resolution mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and next-generation sequencing are examples of some of the advanced analytical methods that are increasingly being used to detect and quantify gastrointestinal (GI) substances with increased sensitivity and specificity. These methods make it possible to identify contaminants at very low concentrations, which is an essential step in the process of verifying the safety of pharmaceutical goods.

Table 3: Advanced Analytical Techniques for GI Detection

Technique	Sensitivity (ppm)	Application
High-Resolution Mass Spectrometry (HRMS)	0.001 ppm	Trace impurity detection
Nuclear Magnetic Resonance (NMR) Spectroscopy	0.01 ppm	Structural elucidation
Next-Generation Sequencing (NGS)	0.0001 ppm	Genetic mutation analysis

When it comes to controlling the hazards that are linked with GIs, the industry is also investigating new techniques of risk management in addition to these improved detection technologies. Through the development of in silico models that are capable of predicting the creation of genotoxic contaminants during the synthesis of active pharmaceutical ingredients (APIs), one potential field of study is being performed. The detection and management of gastrointestinal infections (GIs) in the pharmaceutical business might undergo a revolutionary change as a result of these models, which use machine learning algorithms to analyse enormous datasets of chemical interactions.

7. Future Perspectives and Emerging Trends

It is anticipated that the strategy by which genotoxic impurities are managed will undergo a transformation as the pharmaceutical sector continues to make progress. It is possible that future regulatory changes will concentrate on improving the rules for treating gastrointestinal (GI) conditions, with a particular emphasis on giving better advice for several genotoxic impurities and life-threatening indications. There will be chances to refining the TTC approach and exploring alternate risk management techniques that give more flexibility without sacrificing patient safety as the industry gets more experience in this area. These opportunities will arise as the industry obtains more experience in this area.



Graph 3: Projected Trends in GI Detection and Management

Note: This graph projects future trends in the detection and management of genotoxic impurities, highlighting expected advancements in technology and regulatory approaches.

8. Conclusion

The pharmaceutical industry and regulatory authorities struggle to regulate genotoxic impurities (GIs) in API manufacture. These contaminants may induce genetic abnormalities and cancer, requiring strict restrictions for patient safety. GIs' low concentrations and API production's complex synthetic methods make detection difficult. The International Conference on Harmonisation (ICH) recommendations Q3A(R2), Q3B(R2), and Q3C(R4) emphasise the necessity of impurity identification and control in pharmacological substances and products. These efforts were not enough to meet the special issues of genotoxic impurities, requiring European and U.S. regulatory organisations to offer further recommendations. Sponsors of new medication applications must execute GI risk management methods under EMA and FDA standards. To minimise these hazards, regulatory systems frequently use thresholds of toxicological concern (TTC) to set a conservative safety limit for GIs without particular toxicity evidence. The "staged TTC" allows greater limits for short-term exposure, such as in clinical studies. In response to these changing regulatory requirements, the pharmaceutical industry has created structure-based assessments, fate assessments, and more sensitive analytical methods to control GI hazards. Technology and regulations continue to

improve the identification and control of genotoxic contaminants to protect public health by assuring pharmaceutical product safety and effectiveness. Real-world cases like the Viracept contamination with ethyl methanesulfonate (EMS) demonstrate the need for toxicologists, synthetic chemists, and analytical scientists to work together to manage impurities. As the business matures and regulatory requirements change, genotoxic impurity management will certainly improve, protecting patients and advancing pharmaceutical innovation.

References

International Conference on Harmonisation. (2006). Q3A(R2): Impurities in new drug substances. Retrieved September 25, 2009, from http://www.ich.org/LOB/media/MEDIA422.pdf

International Conference on Harmonisation. (2006). Q3B(R2): Impurities in new drug products. Retrieved September 25, 2009, from http://www.ich.org/LOB/media/MEDIA421.pdf

International Conference on Harmonisation. (2009). Q3C(R4): Impurities: Guideline for residual solvents. Retrieved September 25, 2009, from http://www.ich.org/LOB/media/MEDIA5254.pdf

Committee for Medicinal Products for Human Use, European Medicines Agency. (2006). Guideline on the limits of genotoxic impurities. Retrieved September 25, 2009, from http://www.emea.eu.int/pdfs/human/swp/519902en.pdf

United States Food and Drug Administration: Center for Drug Evaluation and Research. (2008). Guidance for industry: Genotoxic and carcinogenic impurities in drug substances and products: Recommended approaches. Retrieved September 25, 2009, from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf

Kroes, R., Renwick, A. G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., ... & Woutersen, R. A. (2004). Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet. *Food and Chemical Toxicology*, 42(1), 65-83.

Munro, I. C., Kennepohl, E., & Kroes, R. (1999). A procedure for the safety evaluation of flavouring substances. *Food and Chemical Toxicology*, 37(2-3), 207-232.

Rulis, A. M. (1989). Establishing a threshold of regulation. In Bonin, J. J., & Stevenson, D. E. (Eds.), *Risk assessment in setting national priorities* (pp. 271-278). Plenum.

Cheeseman, M. A., Machuga, E. J., & Bailey, A. B. (1999). A tiered approach to threshold of regulation. *Food and Chemical Toxicology*, 37(4), 387-412.

Munro, I. C. (1990). Safety assessment procedures for indirect food additives: An overview. *Regulatory Toxicology and Pharmacology*, 12(1), 2-12.

Committee for Medicinal Products for Human Use, European Medicines Agency. (2008). Question & answers on the CHMP Guideline on the Limits of Genotoxic Impurities.

Retrieved September 25, 2009, from http://www.emea.europa.eu/pdfs/human/swp/43199407en.pdf

Dobo, K. L., Greene, N., Cyr, M. O., & Caron, S. (2006). The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. *Regulatory Toxicology and Pharmacology*, 44(3), 282-293.

Müller, L., Mauthe, R. J., Riley, C. M., Andino, M. M., De Antonis, D., Beels, C., ... & Smith, M. D. (2006). A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. *Regulatory Toxicology and Pharmacology*, 44(3), 198-211.

Doak, S. H., Jenkins, G. J., Johnson, G. E., Quick, E., Parry, E. M., & Parry, J. M. (2007). Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. *Cancer Research*, 67(8), 3904-3911.

Swenberg, J. A., Fryar-Tita, E., Jeong, Y. C., Boysen, G., Starr, T., Walker, V. E., & Albertini, R. J. (2008). Biomarkers in toxicology and risk assessment: Informing critical dose-response relationships. *Chemical Research in Toxicology*, 21(1), 253-265.

Müller, L., Gocke, E., Lave, T., & Pfister, T. (2009). Ethyl methanesulfonate toxicity in Viracept: A comprehensive human risk assessment based on threshold data for genotoxicity. *Toxicology Letters*, In press.

Gocke, E., Müller, L., & Pfister, T. (2009). EMS in Viracept: Initial (‘‘traditional’’) assessment of risk to patients based on linear dose-response relations. *Toxicology Letters*, In press.

Gocke, E., Ballantyne, M., & Whitwell, J. (2009). In vivo MNT and MutaTMmouse studies to define the dose-response relations of the genotoxicity of EMS and ENU. *Toxicology Letters*, In press.

Johnson, G. E., Doak, S. H., Skibinski, D. O., Quick, E., & Parry, J. M. (2009). Linear dose-response of DNA-reactive genotoxins: Recommendations for analysis. *Mutation Research*, In press.

Gocke, E., & Wall, M. (2009). In vivo genotoxicity of EMS: Statistical assessment of the dose-response curves. *Toxicology Letters*, In press.

Lutz, R. W., & Lutz, W. K. (2009). Statistical model to estimate a threshold dose and its confidence limits for the analysis of a sublinear dose-response relationship, exemplified for mutagenicity data. *Mutation Research*, In press.

Müller, L., Gocke, E., Lave, T., & Pfister, T. (2009). Threshold risk assessment for ethyl methanesulfonate toxicity, including susceptibility differences regarding tissue, species and individual age and predisposition. *Toxicology Letters*, In press.

Committee for Medicinal Products for Human Use, European Medicines Agency. (2008). Questions and answers on the follow-up to the contamination of Viracept (nelfinavir) with ethyl mesilate. Retrieved September 25, 2009, from http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viracept/Q&A_Viracept_37580708en.pdf

McGovern, T., & Jacobson-Kram, D. (2006). Regulation of genotoxic and carcinogenic impurities in drug substances and products. *Trends in Analytical Chemistry*, 25(8), 790-795.

Humfrey, C. D. (2007). Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances. *Toxicological Sciences*, 100(1), 24-28.

United States Environmental Protection Agency. (2005). Guidelines for carcinogen risk assessment. Retrieved September 25, 2009, from http://www.cfpub.epa.gov/ncea/cfm/recorddisplay.cfm?deid=116283

Pierson, D. A., Olsen, B. A., Robbins, D. K., & King, J. (2009). Approaches to assessment, testing decisions, and analytical determination of genotoxic impurities in drug substances. *Organic Process Research & Development*, 13(2), 285-291.

Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., & Ames, B. N. (1984). The TD50: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. *Environmental Health Perspectives*, 58, 1-8.

Barlow, S. M., Renwick, A. G., Kleiner, J., Bridges, J. W., Busk, L., Dybing, E., ... & Wurtzen, G. (2006). Risk assessment of substances that are both genotoxic and carcinogenic: Report of an International Conference organized by EFSA and WHO with support of ILSI Europe. *Food and Chemical Toxicology*, 44(10), 1636-1650.

Bos, P. M., Baars, B. J., & van Raaij, M. T. (2004). Risk assessment of peak exposure to genotoxic carcinogens: A pragmatic approach. *Toxicology Letters*, 151(1), 43-50.